Vijaya Diagnostic Centre share price today

Vijaya Diagnostic Centre Ltd's share price was ₹1,437.70 at the close on 5 November 2026. It has been rising for 25 weeks. That is 11.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹870 and ₹1,559, and at that close it sat 82% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Vijaya Diagnostic Centre Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row.

Over the last 5.1 years the share price moved +129% while the NIFTY 500 moved +46%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: foreign funds (FIIs) cut their stake for 5 quarters in a row, indian funds and insurers (DIIs) raised their stake for 6 quarters in a row and revenue up on a year earlier for 11 quarters in a row (every quarter we can compare).

1. Foreign funds (FIIs) cut their stake for 5 quarters in a row

   From 19.6% to 10.7% of the company by the September 2026 quarter.

2. Indian funds and insurers (DIIs) raised their stake for 6 quarters in a row

   From 23.7% to 32.5% of the company by the September 2026 quarter.

3. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹231 crore, +22.9% on a year earlier.

   Why: Revenue rose because the company did more tests and scans, with Hyderabad and Pune adding sales.

   Next results: check whether the new main centres and smaller satellite centres open on the planned schedule.

   From the earnings call on 7 Aug 2026.

For July to September 2026 (the quarter ended 30 September 2026), Vijaya Diagnostic Centre reported revenue of ₹255 crore, up 26.2% from ₹202 crore a year earlier, and a profit of ₹59.0 crore, up 37.2% from ₹43.0 crore.

Vijaya Diagnostic Centre results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 7 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Vijaya Diagnostic Centre closed at ₹1,437.70 on 5 November 2026, up 40.5% from ₹1,023.60 a year earlier (7 November 2025) and up 156.8% over five years. Its highest weekly close since September 2021 was ₹1,558.90 on 18 September 2026.

Vijaya Diagnostic Centre share price: then and now

Weekly closing prices. Each change is the move from that price to the 5 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

276 weekly closes from 17 September 2021 to 5 November 2026.

5 Nov 2026: Vijaya Diagnostic Centre closed at ₹1,437.70, down 0.6% on the week and up 0.1% on the month. Results for July to September 2026: Revenue up 26.2% and profit up 37.2% on a year earlier.

Earlier

• 16 Sep 2026: ex-date for a dividend of ₹2 a share.
• 7 Aug 2026: Vijaya Diagnostic Centre held its results call for April to June 2026. Management guided: Next-12-month expansion: nine hubs, including two in Pune, 10-12 spokes and Pune backend infrastructure.

Vijaya Diagnostic Centre paid ₹2 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.14% at the ₹1,437.70 close on 5 November 2026. The last was a dividend of ₹2 a share, ex-date 16 September 2026.

Vijaya Diagnostic Centre dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Vijaya Diagnostic Centre Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 9 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 7 August 2026, Vijaya Diagnostic Centre's management guided: Next-12-month expansion: nine hubs, including two in Pune, 10-12 spokes and Pune backend infrastructure.

Narasimha Raju, on the call for April to June 2026

What management guided

• FY27 capital spending ₹190-195 crore, including ₹8-10 crore for Andhra land and the Punjagutta laboratory.
• Operating margin above 40% despite potential expansion drag.
• FY27 revenue growth high double-digit.
• Sustainable growth of 15% over 3-5 years viewed achievable.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 7 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

What is changing at Vijaya Diagnostic Centre, from the latest results and calls: mature-cluster operating leverage, phased network expansion and wellness and integrated b2c mix.

• Mature-cluster operating leverage. Mature centers and early hub break-even can absorb fixed costs as volume rises. ⚠ estimate
• Phased network expansion. Planned hubs, spokes and backend infrastructure widen the addressable network beyond Hyderabad. ⚠ estimate
• Wellness and integrated B2C mix. Integrated wellness and imaging packages can add volume and realization without relying on broad price hikes. ⚠ estimate
• Cash-funded buildout. Operating cash generation can fund the current expansion cycle, though free cash flow remains limited while capital spending is elevated. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 22 August 2026.

The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage.

Each change stops working if

• Mature-cluster operating leverage: Mature-center growth slows while new-hub losses rise for two consecutive quarters.
• Phased network expansion: Commissioning slips or the reported network count remains unreconciled.
• Wellness and integrated B2C mix: Package demand weakens or discounting rises materially.
• Cash-funded buildout: Operating cash conversion falls while capital spending remains elevated.

The main risks

• Capital spending and guidance credibility: Capital-spending guidance rose while the rollout count requires reconciliation. ✓ fact
• Price-action deferral: The intended selective price increase was deferred beyond the earlier timing indication. ✓ fact
• Hyderabad concentration and seasonality: The largest geography remains material to group growth and past results show seasonal sensitivity. ✓ fact
• Working-capital interpretation: Working-capital days look elevated in one durability signal, while cash decomposition points to stable component days and capital spending-led cash use. ⚠ estimate

Our read after the latest results, written 22 August 2026.

When Vijaya Diagnostic Centre reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Next hub and spoke commissioning - check whether phased additions stay within the expansion schedule and preserve operating leverage.

Vijaya Diagnostic Centre is on 2 of our India lists: Momentum stocks and Small & mid cap stocks.

Vijaya Diagnostic Centre Ltd earned ₹59.0 Cr of net profit in the Sep 2026 quarter, +37.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹173 Cr. Over 8 years profit has grown 22.1% a year on average. That is 23.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹43.0 Cr.

For the full year, FY26 profit was ₹173 Cr (+20.1% on the year before).

Why profit moved: revenue changed +26.2% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +33.3% and revenue +24.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Vijaya Diagnostic Centre Ltd reported ₹255 Cr of revenue in the Sep 2026 quarter, +26.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 8 years it has grown 15.8% a year on average. The last full year, FY26, came in at ₹814 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Cash conversion exceeds profit on both reported windows. The cash triangle shows that capex, rather than operating leakage, is the main use of operating cash.

The last four reported quarters add to ₹910 Cr.

FY26 revenue was ₹814 Cr, +19.5% on the year before.

Recent pace: the last four quarters grew +24.3% on average, against 15.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +24.3%, against +20.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +33.6%, against +23.1% a year (accelerating).

Vijaya Diagnostic Centre Ltd's operating margin was 44.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 9 years it has been between 32.0% and 44.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The operating-leverage catapult applies because management attributes margin protection to fixed-cost absorption and phased launches. The read fails if new centers add costs faster than mature clusters add volume.

Why the margin moved: operating margin changed +3.5 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 155% of Vijaya Diagnostic Centre Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹271 Cr of operating cash against ₹173 Cr of profit. After ₹261 Cr of spending on assets, ₹10.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 155% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 3.5× depreciation over three years. The next section checks what that spending is building.

Vijaya Diagnostic Centre Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −117 days in FY26, up from −118 days in FY21. It spent ₹772 Cr on assets over the last 3 years. Customers take 9 days to pay, and stock sits for 19 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹814 Cr, each day of that cycle ties up about ₹2.2 Cr, so roughly −₹261 Cr is tied up in the business at any time.

FY26: customers took 9 days to pay and stock sat for 19 days, about 0.6 months of sales sitting as stock, for a full cycle of −117 days, longer than FY21's −118.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 19 days. Customers pay about 9 days after that. Suppliers are paid at 145 days. Together that makes the −117-day cycle.

Spending on assets: ₹772 Cr over the last 3 years, against ₹220 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹35.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Vijaya Diagnostic Centre Ltd's P/E is 72.7×, near the high end of its own history: higher than 75% of past readings. Its usual P/E (the middle reading) is 66.2×, over 5.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +20.0% while the price moved +40.5%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +20.8% a year; about +19.1% a year came from earnings growth and about +1.7 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Worked out from its price on 24 August 2026, Vijaya Diagnostic Centre Ltd's share price assumed profit growth of about 34.6% a year. Over the past 8 years its profit actually grew 22.1% a year. Today its P/E is 72.7×, higher than 75% of its own last 5.1 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 5 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Vijaya Diagnostic Centre Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 23.1%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Vijaya Diagnostic Centre Ltd's story is not scored yet against the checks our research set on 22 August 2026.

NOT YET CHECKED

From the numbers. The normalized read confirms the premium rather than reversing it: margin is above its mid-cycle level and normalized…

From the price. Price stage 2, week 25, above its 200-day line, relative strength falling.

What is not proven yet. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage.

What would change our mind. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage.

The test written in advance. The thesis breaks if the next two reported quarters show revenue growth below the management growth aspiration while operating margin falls below the stated floor, because that would show that new-network spending is not being absorbed by mature-cluster operating leverage. Measured by: the thesis as written as stated by the next result.

The test written in advance. Capex and guidance credibility. Measured by: Capex and guidance credibility FY27_capex ytd cr by the next result.

What the company does. Revenue and profit grew in the latest quarter while operating margin remained above the stated floor. New hubs are reaching break-even early, supporting the spoke-and-hub rollout beyond Hyderabad.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

What the surface reading misses. The surface reading is: Jun 2026 was the highest revenue and net-profit quarter in the supplied eight-quarter series. The research reads it further: The higher quarter is accompanied by 43% operating margin, so the revenue advance did not require a collapse in reported operating profitability.

What the surface reading misses. The surface reading is: Revenue growth was 22.9% and net-profit growth was 35.9% year on year in Jun 2026. The research reads it further: Profit grew faster than revenue, consistent with reported operating leverage rather than a revenue-only expansion.

• 1 · Operating leveragebuilding
• 2 · Value-added mixquiet
• 3 · Management changebuilding
• 4 · Paying down debtquiet
• 5 · Regulatory approvalbuilding
• 6 · Order-book winsquiet
• 7 · Consolidationbuilding
• 8 · Demerger or value unlockquiet
• 9 · Buybackquiet
• 10 · New geographiesquiet
• 11 · More business from existing customersquiet
• 12 · New product launchquiet
• 13 · Mandatory normsquiet
• 14 · A bigger market to servequiet
• 15 · Market-share gainsquiet
• 16 · Asset qualityquiet

Lever 1 · Operating leverage: building. Mature centers and early hub break-even can absorb fixed costs as volume rises. What proves it keeps working: Mature-cluster operating leverage. It stops working if Mature-center growth slows while new-hub losses rise for two consecutive quarters.

Lever 3 · Management change: building. Planned hubs, spokes and backend infrastructure widen the addressable network beyond Hyderabad. What proves it keeps working: Phased network expansion. It stops working if Commissioning slips or the reported network count remains unreconciled.

Lever 5 · Regulatory approval: building. Integrated wellness and imaging packages can add volume and realization without relying on broad price hikes. What proves it keeps working: Wellness and integrated B2C mix. It stops working if Package demand weakens or discounting rises materially.

Lever 7 · Consolidation: building. Operating cash generation can fund the current expansion cycle, though free cash flow remains limited while capex is elevated. What proves it keeps working: Cash-funded buildout. It stops working if Operating cash conversion falls while capex remains elevated.

Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

What Vijaya Diagnostic Centre Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Planned Price Increase Deferred · 7 August 2026. In May 2026, management said it would take roughly a 1% to 1.5% price hike in Q1 or Q2. In Aug 2026, management said no hike had been taken since the prior increase and that pricing would only be reassessed after Q2 and Q3, moving beyond the previously stated timing without explaining the delay; this changes realization assumptions.

Reported Center Count Does Not Reconcile With Additions · 7 August 2026. May 2026 reported 162 centers. By Aug 2026, management reported 166 centers but also said two hubs and six spokes had been commissioned to date, which would imply 170 centers from the prior reported base before any closures or reclassifications. The latest call did not explain the discrepancy, which matters for tracking network rollout and capex productivity.

FY27 Capital Expenditure Guidance Materially Revised Upward · 8 May 2026. Management consistently guided FY27 capital expenditure at INR 100-120 crores in both the Nov 2025 and Feb 2026 calls, covering the same planned expansion of 4-5 hubs and 10-12 spokes. In the May 2026 call, this was revised upward to INR 140-150 crores - a 17-50% increase - with management citing a new automated lab at Punjagutta, Hyderabad and higher center-level costs; the Punjagutta lab project had not been mentioned in either prior call, and the per-center capex for the same hub and spoke count also appears to have increased from the prior guided range. This unexplained revision would materially impact free cash flow projections and capital allocation models.

Expansion Strategy De-acceleration · 13 February 2026. In the November 2025 call, management signaled an aggressive expansion posture, stating that early break-evens in new geographies encouraged them to open "a lot more hubs" than previously planned. However, in the February 2026 call, they pivoted to a conservative stance for FY27, guiding for only 4-5 hubs (down from the 10 planned in FY26) and citing "operational bandwidth" constraints rather than capital availability as the reason to slow down hub additions. Earlier call (Nov 2025): “Bangalore. has broken even much earlier. So, that is kind of encouraging for us to open a lot more hubs than probably what we have mentioned.” Later call (Feb 2026): “For FY27, we will be seeing about 4-5 hubs. It is more in terms of ground-level operational challenges. The decision-making is not based on margin but on operational bandwidth and stabilization.”

Every quote above is taken word for word from the company’s own earnings calls.

Recurring guidance revisions on an otherwise operationally strong base (operating margin 43.8%)

Regulatory and governance record

No SEBI/CBI/ED action or fraud allegation surfaced; sweep returned only unrelated HDFC insider-trading case.

Checked 21 July 2026.

Vijaya Diagnostic Centre Ltd earned a ROCE of 21% in FY26. That is up from a low of 18% in FY23. Its return on capital used (ROIC) is 6.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 21.3% net margin and 0.54× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 21.3% net margin × 0.54× asset turnover × 1.57× leverage (assets divided by equity) ≈ 18.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 18.9% − 12.0% = +6.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Vijaya Diagnostic Centre Ltd has total debt of ₹423 Cr against shareholder equity of ₹957 Cr as of Jun 2026, so its debt is 0.44× its equity. Year by year, that ratio went from 0.39 in FY22 to 0.44 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Vijaya Diagnostic Centre Ltd by 9.0 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 32.5% of the company. Foreign institutions moved −7.5 points over the same period, to 10.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why this happened. Management has outlined further hub and spoke additions, with Pune backend infrastructure and laboratory accreditation as dependencies. Early break-even evidence supports the rollout, but center-count reconciliation remains a monitoring issue.

Over the last two years: Domestic institutions: +9.0 points over 8 quarters, to 32.5%; Foreign institutions: −7.5 points over 8 quarters, to 10.7%; Promoters: −1.4 points over 8 quarters, to 52.5%.

Why the owners changed: foreign institutions moved −7.5 points and domestic institutions +9.0 points over 8 quarters, while promoters moved −1.4 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.

For Vijaya Diagnostic Centre Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why this happened. Management describes pathology and radiology as contributors and identifies wellness demand across retail and corporate customers. This is a mix lever, not a confirmed near-term price lever.

61.3 out of 100, rank 3 of 9 in Diagnostics, with 100% of the evidence available.

Vijaya Diagnostic Centre Ltd scores 61.3 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 3. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.

The four parts add up to the total exactly: 24.8 + 17.5 + 0.3 + 18.7 = 61.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Vijaya Diagnostic Centre ranks 3 of 9 Diagnostics companies on the 4-Factor Sector Score, with 61.3 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Diagnostics, all 9 compared on one page.

Vijaya Diagnostic Centre is the 2nd largest of 9 Diagnostics companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dr Lal Pathlabs. Just below it: Metropolis Healthcare, Thyrocare Technologies, Vimta Labs, Suraksha Diagnostic and Krsnaa Diagnostics.

Diagnostics companies close in size

1. Dr Lal Pathlabs Ltd ₹33,020 crore
2. Vijaya Diagnostic Centre Ltd ₹14,805 crore
3. Metropolis Healthcare Ltd ₹11,320 crore
4. Thyrocare Technologies Ltd ₹7,263 crore
5. Vimta Labs Ltd ₹2,168 crore
6. Suraksha Diagnostic Ltd ₹1,648 crore
7. Krsnaa Diagnostics Ltd ₹1,634 crore

All 9 Diagnostics companies, largest first

Companies close in size in other industries

440. Devyani International Ltd ₹14,845 crore · Quick Service Restaurant - QSR
441. Atul Ltd ₹14,805 crore · Dyes & Pigments
442. Vijaya Diagnostic Centre Ltd ₹14,805 crore
443. Swan Defence and Heavy Industries Ltd ₹14,745 crore · Ship - Docks/Breaking/Repairs
444. Deepak Fertilisers & Petrochemicals Corp Ltd ₹14,738 crore · Fertilisers